Study of dostarlimab for advanced or recurrent endometrial cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a drug called dostarlimab (an immunotherapy that helps your immune system fight cancer) in people with advanced or recurrent endometrial cancer. The goal is to see if the drug is safe and effective for this type of cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have endometrial cancer that is advanced (Stage III or IV) or has come back after initial treatment, and is unlikely to be cured by surgery or radiation alone.
- You must be in good enough health to be active and able to take care of yourself (ECOG 0 or 1).
- If you are able to become pregnant, you must agree to use birth control during the study and for at least 6 months after your last dose.
- You must not have had more than one recurrence of the cancer, and you must not have had certain prior treatments (like other immune checkpoint inhibitors) or certain infections (like hepatitis B or C).
- You must not be pregnant or breastfeeding, and you must be willing to follow all study rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of the immunotherapy drug dostarlimab with standard chemotherapy (carboplatin and paclitaxel) for people with advanced or recurrent endometrial cancer that has a specific genetic feature called dMMR or MSI-H. The goal is to see if this combination works better than chemotherapy alone.
This study is testing the safety of an immunotherapy drug called dostarlimab (Jemperli) in patients with a type of endometrial cancer that has returned, spread, or not improved after previous chemotherapy. The drug works by helping your immune system fight the cancer, and the study is specifically for patients whose tumors have certain genetic features (dMMR or MSI-H).
This study tests a new maintenance therapy (mocertatug rezetecan) to help keep endometrial cancer from coming back after initial chemotherapy and immunotherapy. It may help people whose cancer had a good response to first-line treatment.
This trial tests a new drug called dostarlimab, given with standard chemotherapy, for people with advanced or recurrent endometrial cancer. It aims to see if this combination can help shrink tumors or slow their growth.
This trial tests whether giving the drug dostarlimab before surgery can shrink or control endometrial cancer. It is for people whose tumors have a specific genetic feature (MMR deficiency) that may make the drug more effective.
This Phase 1 trial studies how safe and tolerable it is to add dostarlimab (an immunotherapy) to standard chemo and radiation, followed by more chemotherapy, for stage IIIC endometrial cancer that has spread to lymph nodes. It aims to see whether this combination can be given safely soon after surgery.
Hear when a new Neoplasms, Endometrial trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.